California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT06270082
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: City of Hope, Duarte, California
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Register for Updates
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
NCT05685173
Recruiting
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: City of Hope, Duarte, California
Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL)
Register for Updates
Lemborexant in Delayed Sleep Phase Syndrome
NCT05463861
Recruiting
The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, we will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Stanford Univeristy, Redwood City, California
Conditions: Delayed Sleep Phase Syndrome
Register for Updates
Food Prescriptions to Promote Affordable Diets
NCT05309395
Recruiting
This is an Randomized controlled trial (RCT) to assess the impact of meal planning and affordable grocery delivery on weight loss, dietary quality and health on members of multigenerational Latino households.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/25/2025
Locations: Kaiser Permanente, Pasadena, California
Conditions: Diet, Healthy, Overweight and Obesity
Register for Updates
Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia
NCT04980638
Recruiting
This is an open-label, prospective, genotype-match controlled for primary estimand, non randomized, multicenter, international Phase 2 clinical trial designed to investigate the efficacy and safety of ER004 administered intraamniotically as a treatment for unborn XLHED male subjects.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Register for Updates
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685
Recruiting
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Stanford Cancer Institute, Palo Alto, California
Conditions: Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Bionics Orthotics & Prosthetics, San Diego, California
Conditions: Pareses, Lower Extremity
Register for Updates
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
NCT04472767
Recruiting
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Hepatocellular Carcinoma, HCC
Register for Updates
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
NCT06954805
Recruiting
The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd phase of treatment (consolidation) while those with low-risk disease will be spared of chemotherapy and treated with rituximab consolidation alone. This study is also being done to find out about the usefulness of circulating tumor DNA (ctDNA), a novel blood test which, h... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/24/2025
Locations: Stanford Medical Center, Stanford, California
Conditions: Lymphoma, Lymphoma, B-Cell
Register for Updates
A Study of PHST001 in Advanced Solid Tumors
NCT06840886
Recruiting
PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Advanced Solid Tumors
Register for Updates
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
NCT06815536
Recruiting
The goal of this study is to learn if a few investigational tests can correctly find the gene mutation (mutant allele gyrA 91F) that predicts ciprofloxacin resistance in clinical specimens that harbor Neisseria gonorrhoeae. The main question the study aims to answer: Can the investigational reflex test find the correct gene mutation (Neisseria gonorrhoeae gyrA 91F or gyrA 91S) as compared to the sequenced result? Specimens that are collected for routine clinical care and harbor Neisseria gonor... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/24/2025
Locations: San Francisco Public Health Laboratory, San Francisco, California
Conditions: Neisseria Gonorrheae Infection
Register for Updates
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000
Recruiting
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/24/2025
Locations: Shiley Eye Institute, San Diego, California
Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Register for Updates